

Vaishali Pharma Ltd.

(Formerly known as Vaishali Pharma Pvt. Ltd.)



CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819 (30 Lines)
Fax: +91-22-2892 8833
E-mail : info@vaishalipharma.com
export@vaishalipharma.com
CIN - L52310MH2008PLC181632

Date: 22.08.2019

To,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400051

Dear Sir(s),

Sub: Press Release dated 22.08.2019

NSE Symbol: VAISHALI NSE Series: SM

Enclosed please find the media release dated 22nd August, 2019 which is self-explanatory for your kind perusal and records.

Thanking you,

Yours Sincerely,
For Vaishali Pharma Limited

Dewansh Vasani
Director



Encl: a/a

Press Release

Four New Product Registrations (across different dosages) received in high growth market of Cambodia, Asia.

Mumbai, August 22, 2019, recently, Company has received registration for four products (i.e. Cellargy, Coldaway, Combicough and Coughquit) across different dosages in the Cambodia market. These products have a good demand in the local market of Cambodia. This remarkable achievement in the Cambodia market symbolizes a landmark and enables the Company to reach out more and strengthen its presence in the high growth market of Cambodia, Asia.

Following are the products which have received registrations:

Sr. No.	Product Name	Country	Therapeutic Usage
1	Cellargy	Cambodia	Anti-Allergy
2	Coldaway	Cambodia	Antihistamine
3	Combicough	Cambodia	Antihistamine
4	Coughquit	Cambodia	Antihistamine

About Vaishali Pharma Limited:

Incorporated in the year 2008, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 120 formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.



Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai, our office is also located in Vietnam. Further widening our reach overseas, the Company made a joint venture with D.R. Congo & Kenya based company. The Company exports to countries like Russia, Nicaragua, Papua New Guinea, Kenya, Myanmar, Vietnam, Cambodia, etc.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects.

For more details please visit: www.vaishalipharma.com

For any Investor Relations query, please contact:

Atul Vasani

Chairman & Managing Director

Vaishali Pharma Limited

Email: org@vaishalipharma.com

Note: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local, political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.